Table 2: Implementation of preventive measures for VAE other than VAP.
LTVV: Low tidal volume ventilation;
Short-acting: usage of Propofol and Dexmedetomidine>50%.
Long-acting: usage of Benzodiazepines >50%.
S: Sucralfate; PPI: proton pump inhibitors; H2: H2 receptor blockers.
Dominant usage of S: the usage of Sucralfate ≥1/3.
Dominant usage of PPI and/or H2: the usage of Sucralfate < 1/3.
Monitoring items | N (%) |
Sedative |
Short-acting | 22 (68.7) |
Dexmedetomidine | 17 (53.1) |
Propofol | 5 (15.6) |
Long-acting |
Benzodiazepines | 10 (31.3) |
Fluid balance control |
Negative | 8 (25.0) |
Non-negative | 22 (68.8) |
LTVV |
0~7mL/kg | 3 (9.4) |
7-10mL/kg | 25 (78.1) |
Anti-ulcer drugs |
Dominant usage of S | 6 (18.7) |
Dominant usage of PPI and/or H2 | 19 (59.4) |